{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:50:55Z","timestamp":1766451055195},"reference-count":63,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"S Ghosh has received research support from AbbVie and Pentax"},{"name":"received speaker fees from AbbVie and Janssen"},{"name":"steering committees for AbbVie, Bristol-Myers Squibb, Janssen, Novo Nordisk, Pfizer and Receptos"},{"name":"educational activities from Abbvie, Merck Sharp, Dohme Ltd, Ferring and Dr Falk"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.2217\/imt-2015-0031","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T12:21:10Z","timestamp":1462278070000},"page":"495-502","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Tofacitinib in Ulcerative Colitis"],"prefix":"10.1080","volume":"8","author":[{"given":"Thomas P","family":"Archer","sequence":"first","affiliation":[{"name":"NIHR Biomedical Research Unit in Gastrointestinal & Liver Diseases, Nottingham University Hospitals NHS Trust & The University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon W","family":"Moran","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Unit in Gastrointestinal & Liver Diseases, Nottingham University Hospitals NHS Trust & The University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Clinic, University of Calgary, TRW Building, 3280 Hospital DR NW, Calgary, T2N 4N1, Calgary,, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.224154"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.052"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04986.x"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.024"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2009.09.004"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3410\/M4-5"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00211-5"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00644.x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"issue":"7","key":"e_1_3_2_14_1","first-page":"1347","article-title":"JAK2, a third member of the JAK family of protein tyrosine kinases","volume":"7","author":"Harpur AG","year":"1992","unstructured":"Harpur AG , AndresAC, ZiemieckiA, AstonRR, WilksAF. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene7(7), 1347\u20131353 (1992).","journal-title":"Oncogene"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm909"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.10.004"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.03.013"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.01.010"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.06.008"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81166-6"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.032"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.148"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6374"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5237.797"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5237.800"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/377065a0"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.207464"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.12.015"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"e_1_3_2_31_1","unstructured":"Pfizer . Advisory committee meetingtofacitinib for the treatment of rheumatoid arthritis NDA 203214 briefing document. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM302960."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1358"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.01.041"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03200.x"},{"issue":"5","key":"e_1_3_2_37_1","first-page":"491","article-title":"CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders","volume":"10","author":"West K","year":"2009","unstructured":"West K . CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs10(5), 491\u2013504 (2009).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"issue":"3","key":"e_1_3_2_42_1","first-page":"170","article-title":"Tofacitinib (CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: phase 3 study patient-reported outcomes in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs","volume":"70","author":"Kremer Z-Gl J HS","year":"2011","unstructured":"Kremer Z-Gl J HS , FleischmannR, GenoveseMet al. Tofacitinib (CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: phase 3 study patient-reported outcomes in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs. Ann. Rheum. Dis.70(Suppl. 3), 170 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_43_1","first-page":"718","article-title":"Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month phase 3 study","volume":"63","author":"Burmester Rb","year":"2011","unstructured":"Burmester Rb , Gerd-R\u00fcdigerC-SC, WollenhauptJet al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month phase 3 study. Arthritis Rheum.63, 718 (2011).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_44_1","first-page":"2592","article-title":"Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study","volume":"63","author":"Van Der Heijde D","year":"2011","unstructured":"Van Der Heijde D , TanakaY, FleischmannRet al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study. Arthritis Rheum.63, 2592 (2011).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"e_1_3_2_48_1","unstructured":"Pfizer . OCTAVE Trial. www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_positive_top_line_results_from_two_phase_3_trials_of_oral_tofacitinib_in_adults_with_moderate_to_severe_ulcerative_colitis."},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302830"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20927"},{"key":"e_1_3_2_52_1","unstructured":"National Institutes of Health . Clinicaltrials database. https:\/\/clinicaltrials.gov\/."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04127.x"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38745"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201348"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0240-z"},{"issue":"10","key":"e_1_3_2_58_1","first-page":"478","article-title":"Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy subjects and rheumatoid arthritis patients","volume":"65","author":"Galien R","year":"2013","unstructured":"Galien R , Vayssie reB, De VosSet al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy subjects and rheumatoid arthritis patients. Arthritis Rheum.65(Suppl. 10), 478 (2013).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312810666151223103353"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804063"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801142b"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1226"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2014.995747"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13745"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208279"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2015-0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:36:40Z","timestamp":1715945800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2015-0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.2217\/imt-2015-0031"],"URL":"https:\/\/doi.org\/10.2217\/imt-2015-0031","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}